LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

Home・Stock List・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Open

SectorHealthcare

36.15 -3.21

Buy Sell

Overview

Share price change

24h

Current

Min

36.2

Max

37.93

Key metrics
By Trading Economics
Income	7.3M -123M
Sales	3.7M 3.9M
EPS	-1.29
Profit margin	-3,161.261
Employees	594
EBITDA	20M -122M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+128.79% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-140M 4.3B
Previous open	39.36
Previous close	36.15

News Sentiment

By Acuity

71%

29%

313 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

30.39 / 33.46 Support & Resistance

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 May 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 May 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 May 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 May 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 May 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 May 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 May 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 May 2026, 10:21 UTC

Earnings

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 May 2026, 06:05 UTC

Earnings

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 May 2026, 23:55 UTC

Earnings

Review & Preview: Still Going Strong -- Barrons.com

8 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 20:49 UTC

Earnings

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 May 2026, 20:25 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Net $115M

8 May 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 May 2026, 19:18 UTC

Earnings

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 May 2026, 19:16 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:08 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:05 UTC

Earnings

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 May 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 May 2026, 18:51 UTC

Earnings

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 May 2026, 18:49 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 18:41 UTC

Earnings

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 May 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 May 2026, 17:14 UTC

Earnings

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 May 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

128.79% upside

12 Months Forecast

Average 85.75 USD 128.79%

High 97 USD

Low 67 USD

Based on 9 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Crinetics Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

313 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.